YB Urban Renewal Residential Development Ltd, formerly known as Cannassure Therapeutics Ltd, is an Israel-based urban renewal company. The Company is engaged mainly in urban renewal projects. In the urban renewal projects sector, the Company partakes in activities that aim to clear out areas of inner cities deemed to be neglected, unused and loosely maintained, in favor of new multifamily housing, business areas, as well as other developments improving the city landscape. The Firm aims to achieve economic, cultural and environmental renewal of the neglected inner city areas. The Company cooperates with a range of specialists in the field of urban renewal with knowledge and experience in urban planning and construction work.

Employees

Sector

Real Estate Development & Operations

More about the company

Market Cap	28.62M 9.42M 8.22M 7.76M 7.05M 13.2M 904M 13.26M 92.94M 35.87M 460M 35.4M 34.61M 1.48B	P/E 2024	-4.93x	P/E 2025	-9.22x
Enterprise Value	28.74M 9.46M 8.25M 7.79M 7.07M 13.25M 908M 13.31M 93.32M 36.01M 462M 35.54M 34.75M 1.49B	EV / Sales 2024	376x	EV / Sales 2025	-
Free-Float	54.18%	Yield 2024 *	-	Yield 2025	-

08-30	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
05-03	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-03	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
11-13	Y.B Urban Renewal - Residential Development Ltd announced that it expects to receive ILS 0.53001 million in funding	CI
10/09/25	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
01/09/24	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI
11/07/24	Cannassure Therapeutics Ltd will Change its Name to Y.B URBAN RENEWAL - RESIDENTIAL DEVELOPMENT LTD	CI
27/03/24	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
27/03/24	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
31/08/23	Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	CI
26/03/23	Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/08/21	Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority	CI

26/02/21	DanCann Pharma A/S : publishes Year-end report for 2020	AQ
18/01/21	Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology	AQ
18/01/21	Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology	AQ
15/12/20	DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)	AQ
19/11/20	Lipidor : publishes interim report for Q3 2020	AQ

Manager	Title	Age	Since
Ada Bar Kama CEO	Chief Executive Officer	56	31/03/2022
Oren Attiya DFI	Director of Finance/CFO	45	-
Daniel Shapira AUD	Comptroller/Controller/Auditor	72	26/06/2019

Director	Title	Age	Since
Nir Peles CHM	Chairman	53	09/12/2021
Shimon Bar-Kama BRD	Director/Board Member	74	04/12/2018
Varda Kalal BRD	Director/Board Member	58	14/02/2022

Cannassure Therapeutics Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

CSURE

IL0001110134

Real Estate Development & Operations

Valuation: Cannassure Therapeutics Ltd

Latest news: Cannassure Therapeutics Ltd

Press Releases: Cannassure Therapeutics Ltd

Quotes and Performance

Managers and Directors: Cannassure Therapeutics Ltd

Other Real Estate Development & Operations

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CANNASSURE THERAPEUTICS LTD	-7.54%	-22.20%	-	-	9.42M
SUN HUNG KAI PROPERTIES LIMITED	-0.46%	-0.46%	+13.91%	+33.46%	39.78B
MITSUBISHI ESTATE CO., LTD.	-1.77%	+0.31%	+6.67%	+73.79%	27.69B
EMAAR PROPERTIES	-1.53%	+6.61%	-16.40%	+64.82%	27.96B
MITSUI FUDOSAN CO., LTD.	-1.33%	-0.40%	-7.45%	+29.39%	25.46B
CHINA RESOURCES LAND LIMITED	+0.49%	-1.78%	-9.08%	-11.06%	26.03B
ALPHA DHABI HOLDING	-0.13%	+4.07%	-26.15%	-61.90%	20.9B
CK ASSET HOLDINGS LIMITED	0.00%	-3.55%	+24.68%	+13.19%	20.6B
SUMITOMO REALTY & DEVELOPMENT CO., LTD.	-2.06%	-0.78%	-2.51%	+57.37%	18.75B
HONGKONG LAND HOLDINGS LIMITED	+2.61%	+1.89%	+29.92%	+146.86%	18.41B
Average	-1.17%	+0.82%	+1.51%	+38.43%	25.06B
Weighted average by Cap.	-0.55%	+0.85%	+1.41%	+37.26%

	2024	2025
Net sales	76K 25.02K 21.82K 20.6K 18.71K 35.05K 2.4M 35.2K 247K 95.24K 1.22M 94K 91.92K 3.93M	-
Net income	-3.68M -1.21M -1.06M -996K -905K -1.7M -116M -1.7M -11.93M -4.61M -59.03M -4.55M -4.44M -190M	-3M -986K -860K -812K -738K -1.38M -94.66M -1.39M -9.73M -3.75M -48.12M -3.71M -3.62M -155M
Net Debt	980K 323K 281K 266K 241K 452K 30.96M 454K 3.18M 1.23M 15.74M 1.21M 1.19M 50.65M	115K 37.87K 33.02K 31.18K 28.31K 53.04K 3.63M 53.26K 373K 144K 1.85M 142K 139K 5.94M